Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 95,959 | 176,777 | 75,139 | 101,842 | 18,508 |
| Marketable Securities | 70,414 | 16,928 | 19,758 | N/A | N/A |
| TOTAL | $166,751 | $194,491 | $96,646 | $102,816 | $21,354 |
| Non-Current Assets | |||||
| Investments And Advances | 22,118 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 151 | 37 | 73 | 109 | 144 |
| TOTAL | $22,269 | $37 | $73 | $109 | $144 |
| Total Assets | $189,020 | $194,528 | $96,719 | $102,925 | $21,498 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,994 | 531 | 186 | 1,702 | 2,723 |
| Accrued Expenses | 3,581 | 3,953 | 5,403 | 3,244 | 2,424 |
| TOTAL | $5,728 | $4,510 | $5,654 | $5,049 | $5,287 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 214,625 |
| TOTAL | $N/A | $N/A | $N/A | $1 | $214,625 |
| Total Liabilities | $5,728 | $4,510 | $5,654 | $5,050 | $219,912 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,675 | 30,393 | 31,914 | 21,375 | 21,355 |
| Common Shares | 3 | 3 | 2 | 2 | 1 |
| Retained earnings | -264,491 | -256,373 | -249,744 | -241,593 | -235,240 |
| Other shareholders' equity | -23 | 7 | 30 | 0 | 0 |
| TOTAL | $183,292 | $190,018 | $91,065 | $97,875 | $-198,414 |
| Total Liabilities And Equity | $189,020 | $194,528 | $96,719 | $102,925 | $21,498 |